NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	0.8470 €	-1.97%	37,640
26-06-16	0.8640 €	-4.00%	77,227
26-06-15	0.9000 €	0.00%	22,958
26-06-12	0.9000 €	+1.01%	10,956
26-06-11	0.8910 €	-1.00%	12,010

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-17 am EDT			5-day change	1st Jan Change
0.8470 ^EUR	-1.97%		-5.89%	-28.10%

Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
Jun. 01	NFL Biosciences validates breakthrough in personalized medicine

Market Cap	10.73M 12.44M 9.87M 9.29M 17.45M 1.17B 17.6M 117M 45.53M 576M 46.7M 45.7M 1.99B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	9.11M 10.56M 8.38M 7.89M 14.82M 997M 14.94M 99.3M 38.66M 489M 39.65M 38.8M 1.69B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
Jun. 01	NFL Biosciences validates breakthrough in personalized medicine
May. 26	Glimmers of hope for Middle East peace grow brighter
May. 26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
May. 25	NFL Biosciences files new patent application
May. 25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
May. 11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
May. 04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
Apr. 15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI
Apr. 13	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
Mar. 12	JCDecaux, Maurel & Prom, Voltalia... stocks to watch today in Paris
Mar. 11	NFL BIOSCIENCES Secures EUR 500,000 Loan from Bpifrance	CI

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Jun. 17	NFL Biosciences : compte rendu de l’assemblée générale mixte du 17 juin 2026
Jun. 13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
Jun. 02	Bourse : STMicro embrasse l'IA, BNP conteste un jugement et HPE on fire
Jun. 02	L'IA avale (toujours) tout
Jun. 01	NFL Biosciences valide une avancée en médecine personnalisée

1 day	-1.97%
1 week	-5.89%
Current month	-17.45%
1 month	-3.75%
3 months	-20.84%
6 months	-22.58%
Current year	-28.10%

1 week	0.84	0.91
1 month	0.84	1.15
Current year	0.84	1.85
1 year	0.84	1.85
3 years	0.84	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-1.97%	-5.89%	-28.22%	-72.68%	12.7M
ARGENX SE	+3.23%	+2.25%	+65.02%	+113.87%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+1.20%	+47.67%	+36.75%	43.86B
BIONTECH SE	+3.04%	+7.05%	-12.15%	-18.06%	22.63B
INSMED INCORPORATED	+3.07%	+7.15%	-1.82%	+392.25%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	+2.68%	+2.14%	+23.06%	-34.52%	15.84B
GENMAB A/S	+5.27%	+1.87%	+13.67%	-38.81%	14.83B
EXELIXIS, INC.	+0.65%	-0.27%	+26.80%	+174.70%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.09%	+2.94%	+18.51%	-	12.66B
PHARMAESSENTIA CORPORATION	+1.92%	+2.43%	+112.68%	+232.59%	11.68B
Average	+1.83%	+1.34%	+26.52%	+87.34%	20.98B
Weighted average by Cap.	+2.22%	+2.15%	+37.13%	+98.46%

	2024	2025
Net sales	46 53.32 42.29 39.81 74.8 5.03K 75.43 501.18 195.12 2.47K 200.12 195.85 8.54K	188 217.92 172.84 162.69 305.7 20.57K 308.27 2.05K 797.46 10.09K 817.9 800.42 34.92K
Net income	-2.08M -2.41M -1.91M -1.8M -3.38M -228M -3.41M -22.67M -8.83M -112M -9.05M -8.86M -386M	-3.32M -3.85M -3.05M -2.87M -5.4M -363M -5.44M -36.15M -14.07M -178M -14.43M -14.13M -616M
Net Debt	-2.07M -2.4M -1.91M -1.79M -3.37M -227M -3.4M -22.58M -8.79M -111M -9.02M -8.82M -385M	-1.62M -1.88M -1.49M -1.4M -2.63M -177M -2.66M -17.64M -6.87M -86.95M -7.05M -6.89M -301M